Marcello Viscovo

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

InflaMix Predicts Severe CRS, ICU Admission, and Progression-Free Survival After CAR-T Therapy in LBCL.

InflaMix Predicts Severe CRS, ICU Admission, and Progression-Free Survival After CAR-T Therapy in LBCL.

Journal: European journal of haematology

Published: July 24, 2026

Classical Hodgkin Lymphoma Today.

Classical Hodgkin Lymphoma Today.

Journal: Mediterranean journal of hematology and infectious diseases

Published: May 12, 2026

Deciphering the Complex Intertwining Between Cytopenia and Transfusion Needs After CAR-T-Cell Therapy for B-Cell Malignancies.

Deciphering the Complex Intertwining Between Cytopenia and Transfusion Needs After CAR-T-Cell Therapy for B-Cell Malignancies.

Journal: Life (Basel, Switzerland)

Published: July 23, 2025

Tracking Inflammation in CAR-T Therapy: The Emerging Role of Serum Amyloid A (SAA).

Tracking Inflammation in CAR-T Therapy: The Emerging Role of Serum Amyloid A (SAA).

Journal: Cancers

Published: July 14, 2025

Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study.

Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study.

Journal: Blood advances

Published: June 05, 2025

Strain-derived myocardial work indices in adult cancer survivors: results from an observational study and comparison with available reference ranges.

Strain-derived myocardial work indices in adult cancer survivors: results from an observational study and comparison with available reference ranges.

Journal: Cardio-oncology (London, England)

Published: May 03, 2025

Frail is not fail: Limited impact of comorbidities on non-relapse mortality and safety in patients with LBCL treated with CAR-T.

Frail is not fail: Limited impact of comorbidities on non-relapse mortality and safety in patients with LBCL treated with CAR-T.

Journal: British journal of haematology

Published: April 21, 2025

Treatment outcomes in elderly patients ≥ 65 years with Large B-Cell Lymphoma (LBCL): a real-world single center experience focusing on potential CD19-CAR-T eligibility in second line.

Treatment outcomes in elderly patients ≥ 65 years with Large B-Cell Lymphoma (LBCL): a real-world single center experience focusing on potential CD19-CAR-T eligibility in second line.

Journal: Annals of hematology

Published: April 11, 2025

Heterogeneous Surface CD79b Expression in Aggressive B-Cell Lymphomas Assessed by Flow Cytometry on Lymph Node Biopsies.

Heterogeneous Surface CD79b Expression in Aggressive B-Cell Lymphomas Assessed by Flow Cytometry on Lymph Node Biopsies.

Journal: Cancers

Published: October 25, 2024

Cardio-oncology: Emerging Concepts in Cardiovascular Sequelae of Cancer Therapies, Translational Research and Reverse Cardio-oncology.

Cardio-oncology: Emerging Concepts in Cardiovascular Sequelae of Cancer Therapies, Translational Research and Reverse Cardio-oncology.

Journal: European cardiology

Published: October 22, 2024

Baseline Tumor Burden Assessed With AI-Guided PET/CT Total Metabolic Tumor Volume (TMTV) and LDH Levels Predict Efficacy of CAR-T in Aggressive B-Cell Lymphoma.

Baseline Tumor Burden Assessed With AI-Guided PET/CT Total Metabolic Tumor Volume (TMTV) and LDH Levels Predict Efficacy of CAR-T in Aggressive B-Cell Lymphoma.

Journal: Hematological oncology

Published: October 16, 2024

Vascular inflammation in patients undergoing anti-CD19 chimeric antigen receptor-T cells for haematologic malignancies: a call for cardiovascular surveillance.

Vascular inflammation in patients undergoing anti-CD19 chimeric antigen receptor-T cells for haematologic malignancies: a call for cardiovascular surveillance.

Journal: European heart journal

Published: October 12, 2024

Showing 1-12 of 29

Last Updated: 09/26/2026